Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Accumulated Expenses (2022 - 2025)

Phathom Pharmaceuticals (PHAT) has disclosed Accumulated Expenses for 4 consecutive years, with $14.8 million as the latest value for Q3 2025.

  • On a quarterly basis, Accumulated Expenses rose 415.43% to $14.8 million in Q3 2025 year-over-year; TTM through Sep 2025 was $14.8 million, a 415.43% increase, with the full-year FY2024 number at $2.3 million, up 131.81% from a year prior.
  • Accumulated Expenses was $14.8 million for Q3 2025 at Phathom Pharmaceuticals, up from $83000.0 in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $14.8 million in Q3 2025 to a low of $83000.0 in Q2 2025.
  • A 4-year average of $5.1 million and a median of $2.6 million in 2024 define the central range for Accumulated Expenses.
  • Biggest YoY gain for Accumulated Expenses was 415.43% in 2025; the steepest drop was 95.76% in 2025.
  • Phathom Pharmaceuticals' Accumulated Expenses stood at $4.3 million in 2022, then crashed by 76.44% to $1.0 million in 2023, then soared by 131.81% to $2.3 million in 2024, then soared by 532.66% to $14.8 million in 2025.
  • Per Business Quant, the three most recent readings for PHAT's Accumulated Expenses are $14.8 million (Q3 2025), $83000.0 (Q2 2025), and $426000.0 (Q1 2025).